Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 87% Improvement Relative Risk Ventilation 77% Respiratory failure 88% c19early.org/k d'Ettorre et al. Probiotics for COVID-19 LATE Is late treatment with probiotics beneficial for COVID-19? Retrospective 70 patients in Italy Lower progression with probiotics (p=0.011) d'Ettorre et al., Frontiers in Medicine, doi:10.3389/fmed.2020.00389 Favors probiotics Favors control
Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
d'Ettorre et al., Frontiers in Medicine, doi:10.3389/fmed.2020.00389
d'Ettorre et al., Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary.., Frontiers in Medicine, doi:10.3389/fmed.2020.00389
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 70 hospitalized patients in Italy, 28 treated with probiotic Sivomixx, showing lower risk of respiratory failure and faster recovery with treatment.
The immune effects of probiotics are strain-specific.
risk of death, 87.0% lower, RR 0.13, p = 0.14, treatment 0 of 28 (0.0%), control 4 of 42 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 76.9% lower, RR 0.23, p = 0.51, treatment 0 of 28 (0.0%), control 2 of 42 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
respiratory failure, 88.4% lower, OR 0.12, p = 0.01, treatment 28, control 42, inverted to make OR<1 favor treatment, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
d'Ettorre et al., 7 Jul 2020, retrospective, Italy, peer-reviewed, 17 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: ORIGINAL RESEARCH published: 07 July 2020 doi: 10.3389/fmed.2020.00389 Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19 Edited by: Alessandro Russo, University of Pisa, Italy Reviewed by: Antonio Vena, University of Genoa, Italy Alice Picciarella, Policlinico Casilino, Italy *Correspondence: Giancarlo Ceccarelli giancarlo.ceccarelli@uniroma1.it † These authors share first authorship Specialty section: This article was submitted to Infectious Diseases, Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine Received: 09 May 2020 Accepted: 22 June 2020 Published: 07 July 2020 Citation: d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, Ruberto F, Rossi G, Celani L, Scagnolari C, Mastropietro C, Trinchieri V, Recchia GE, Mauro V, Antonelli G, Pugliese F and Mastroianni CM (2020) Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front. Med. 7:389. doi: 10.3389/fmed.2020.00389 Frontiers in Medicine | www.frontiersin.org Gabriella d’Ettorre 1† , Giancarlo Ceccarelli 1*† , Massimiliano Marazzato 1 , Giuseppe Campagna 2 , Claudia Pinacchio 1 , Francesco Alessandri 3 , Franco Ruberto 3 , Giacomo Rossi 4 , Luigi Celani 1 , Carolina Scagnolari 5 , Cristina Mastropietro 1 , Vito Trinchieri 1 , Gregorio Egidio Recchia 1 , Vera Mauro 1 , Guido Antonelli 5 , Francesco Pugliese 3 and Claudio Maria Mastroianni 1 1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, 2 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy, 3 Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy, 4 School of Biosciences, Veterinary Medicine University of Camerino, Camerino, Italy, 5 Laboratory of Virology, Department of Molecular Medicine, Affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University, Rome, Italy Background: Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods: We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation. Results: The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit